• Explore /
  • Poster
  • / Phase III APACT trial of adjuvant <em>nab-</em>paclitaxel plus gemcitabine (<em>nab</em>-P + Gem) versus gemcitabine (Gem) alone for patients with resected pancreatic cancer (PC): Outcomes by geographic region.

Phase III APACT trial of adjuvant nab-paclitaxel plus gemcitabine (nab-P + Gem) versus gemcitabine (Gem) alone for patients with resected pancreatic cancer (PC): Outcomes by geographic region.

Abstract Poster

Authors

null

Michele Reni

IRCCS Ospedale, San Raffaele Scientific Institute, Milan, Italy

Michele Reni , Hanno Riess , Eileen Mary O'Reilly , Joon Oh Park , Hassan Hatoum , Berta Laquente Saez , Tapio Salminen , Helmut Oettle , Rafael Lopez , Scot D. Dowden , Meinolf Karthaus , Josep Tabernero , Eric Van Cutsem , Philip Agop Philip , David Goldstein , Jordan Berlin , Margaret A. Tempero

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2020 ASCO Virtual Scientific Program

Session Type

Poster Discussion Session

Session Title

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Track

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Sub Track

Pancreatic Cancer

Clinical Trial Registration Number

NCT01964430

Citation

J Clin Oncol 38: 2020 (suppl; abstr 4515)

DOI

10.1200/JCO.2020.38.15_suppl.4515

Abstract #

4515

Poster Bd #

123

Abstract Disclosures

Similar Posters

First Author: Mustapha Ali Tehfe

First Author: Michael J. Pishvaian

First Author: Gang Jin

First Author: Akihiro Ohba